CG Oncology publishes Phase 3 bladder cancer trial results in Lancet

July 27, 2026 6:46 PM

CG Oncology, Inc. (NASDAQ: CGON) announced the publication of results from its pivotal Phase 3 BOND-003 Cohort C trial in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found